Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

Pathologically proven NSCLC
Ineligibile for curative treatment (namely, stage IIIb or IV)
History of one to three prior systemic chemotherapy tumors without active EGFR mutations (exon 19 deletion, L858R mutation in exon 21)
At least one lesion that was unidimensionally measurable by computed tomography (by RECIST 1.1)
18 years old or older
Performance status ECOG 0-2
Adequate organ function as evidenced by the following:
* Absolute neutrophil count \> 1.0 x 109/L
* Platelets \> 75 x 109/L
* Total bilirubin ≤ 1.5 UNL
* AST and/or ALT \< 5 UNL
* Creatinine clearance ≥ 45mL/min

Previous EGFR TKI therapy history
Systemic anticancer therapy within the previous 3 weeks
Other invasive malignancy within the past 2 years except non-melanoma skin cancer, in situ cervix cancer, or papillary thyroid cancer
Other concurrent illness that would preclude study participation (severe heart disease)
Other concurrent physical condition (e.g., infectious disease) that would preclude study participation
Pregnant or nursing

Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)